Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients

Roger C. Carroll, Robert Craft, Gregory L. Whitaker, Carolyn C. Snider, Ryan K. Kirby, Robert Elder, Mark D. Hennessey

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The anticoagulant effect of enoxaparin is readily observed by Thrombelastography (TEG®), particularly on the reaction time (R) to form a clot, and is completely reversed by heparinase. In this study, recalcified citrated whole blood with heparinase (CNHR) and without (CNR), along with TEG R time, was used to derive a delta R (CNR - CNHR). This delta R (ΔR) was then used to measure enoxaparin anticoagulation, which was correlated by linear regression (r2 = 0.806) with plasma anti-Xa in 48 thrombophilic pregnancy patients. In a follow up study whole blood from 15 thrombophilic and 15 normal pregnancy subjects was titrated ex vivo with enoxaparin and TEG ΔR determined. Linear dose responses (all r2 > 0.9) of ΔR versus plasma enoxaparin concentration were obtained for each subject. A large variation in slope was observed for both thrombophilic (> 7 fold, 217 to 1588 s ΔR/unit anti-Xa) and normal (> 3 fold, 788 to 2758) pregnancy subjects. The average slope for the thrombophilic group (710 s ΔR/unit anti-Xa) was significantly (P = 0.002) lower than the normal pregnancy group (1354 s), indicating resistance to enoxaparin anticoagulation in the thrombophilic group. This technique may help gauge the appropriate dose of enoxaparin for each individual, check for residual anticoagulation before invasive procedures, and perhaps help screen for thrombophilic subjects.

Original languageEnglish (US)
Pages (from-to)367-370
Number of pages4
JournalThrombosis Research
Volume120
Issue number3
DOIs
StatePublished - Jun 12 2007

Fingerprint

Thrombelastography
Enoxaparin
Pregnancy
Heparin Lyase
Anticoagulants
Linear Models

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients. / Carroll, Roger C.; Craft, Robert; Whitaker, Gregory L.; Snider, Carolyn C.; Kirby, Ryan K.; Elder, Robert; Hennessey, Mark D.

In: Thrombosis Research, Vol. 120, No. 3, 12.06.2007, p. 367-370.

Research output: Contribution to journalArticle

Carroll, Roger C. ; Craft, Robert ; Whitaker, Gregory L. ; Snider, Carolyn C. ; Kirby, Ryan K. ; Elder, Robert ; Hennessey, Mark D. / Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients. In: Thrombosis Research. 2007 ; Vol. 120, No. 3. pp. 367-370.
@article{91dab7df3ad24146b3635f03f37ea610,
title = "Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients",
abstract = "The anticoagulant effect of enoxaparin is readily observed by Thrombelastography (TEG{\circledR}), particularly on the reaction time (R) to form a clot, and is completely reversed by heparinase. In this study, recalcified citrated whole blood with heparinase (CNHR) and without (CNR), along with TEG R time, was used to derive a delta R (CNR - CNHR). This delta R (ΔR) was then used to measure enoxaparin anticoagulation, which was correlated by linear regression (r2 = 0.806) with plasma anti-Xa in 48 thrombophilic pregnancy patients. In a follow up study whole blood from 15 thrombophilic and 15 normal pregnancy subjects was titrated ex vivo with enoxaparin and TEG ΔR determined. Linear dose responses (all r2 > 0.9) of ΔR versus plasma enoxaparin concentration were obtained for each subject. A large variation in slope was observed for both thrombophilic (> 7 fold, 217 to 1588 s ΔR/unit anti-Xa) and normal (> 3 fold, 788 to 2758) pregnancy subjects. The average slope for the thrombophilic group (710 s ΔR/unit anti-Xa) was significantly (P = 0.002) lower than the normal pregnancy group (1354 s), indicating resistance to enoxaparin anticoagulation in the thrombophilic group. This technique may help gauge the appropriate dose of enoxaparin for each individual, check for residual anticoagulation before invasive procedures, and perhaps help screen for thrombophilic subjects.",
author = "Carroll, {Roger C.} and Robert Craft and Whitaker, {Gregory L.} and Snider, {Carolyn C.} and Kirby, {Ryan K.} and Robert Elder and Hennessey, {Mark D.}",
year = "2007",
month = "6",
day = "12",
doi = "10.1016/j.thromres.2006.10.011",
language = "English (US)",
volume = "120",
pages = "367--370",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients

AU - Carroll, Roger C.

AU - Craft, Robert

AU - Whitaker, Gregory L.

AU - Snider, Carolyn C.

AU - Kirby, Ryan K.

AU - Elder, Robert

AU - Hennessey, Mark D.

PY - 2007/6/12

Y1 - 2007/6/12

N2 - The anticoagulant effect of enoxaparin is readily observed by Thrombelastography (TEG®), particularly on the reaction time (R) to form a clot, and is completely reversed by heparinase. In this study, recalcified citrated whole blood with heparinase (CNHR) and without (CNR), along with TEG R time, was used to derive a delta R (CNR - CNHR). This delta R (ΔR) was then used to measure enoxaparin anticoagulation, which was correlated by linear regression (r2 = 0.806) with plasma anti-Xa in 48 thrombophilic pregnancy patients. In a follow up study whole blood from 15 thrombophilic and 15 normal pregnancy subjects was titrated ex vivo with enoxaparin and TEG ΔR determined. Linear dose responses (all r2 > 0.9) of ΔR versus plasma enoxaparin concentration were obtained for each subject. A large variation in slope was observed for both thrombophilic (> 7 fold, 217 to 1588 s ΔR/unit anti-Xa) and normal (> 3 fold, 788 to 2758) pregnancy subjects. The average slope for the thrombophilic group (710 s ΔR/unit anti-Xa) was significantly (P = 0.002) lower than the normal pregnancy group (1354 s), indicating resistance to enoxaparin anticoagulation in the thrombophilic group. This technique may help gauge the appropriate dose of enoxaparin for each individual, check for residual anticoagulation before invasive procedures, and perhaps help screen for thrombophilic subjects.

AB - The anticoagulant effect of enoxaparin is readily observed by Thrombelastography (TEG®), particularly on the reaction time (R) to form a clot, and is completely reversed by heparinase. In this study, recalcified citrated whole blood with heparinase (CNHR) and without (CNR), along with TEG R time, was used to derive a delta R (CNR - CNHR). This delta R (ΔR) was then used to measure enoxaparin anticoagulation, which was correlated by linear regression (r2 = 0.806) with plasma anti-Xa in 48 thrombophilic pregnancy patients. In a follow up study whole blood from 15 thrombophilic and 15 normal pregnancy subjects was titrated ex vivo with enoxaparin and TEG ΔR determined. Linear dose responses (all r2 > 0.9) of ΔR versus plasma enoxaparin concentration were obtained for each subject. A large variation in slope was observed for both thrombophilic (> 7 fold, 217 to 1588 s ΔR/unit anti-Xa) and normal (> 3 fold, 788 to 2758) pregnancy subjects. The average slope for the thrombophilic group (710 s ΔR/unit anti-Xa) was significantly (P = 0.002) lower than the normal pregnancy group (1354 s), indicating resistance to enoxaparin anticoagulation in the thrombophilic group. This technique may help gauge the appropriate dose of enoxaparin for each individual, check for residual anticoagulation before invasive procedures, and perhaps help screen for thrombophilic subjects.

UR - http://www.scopus.com/inward/record.url?scp=34249932188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249932188&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2006.10.011

DO - 10.1016/j.thromres.2006.10.011

M3 - Article

VL - 120

SP - 367

EP - 370

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 3

ER -